These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25496225)

  • 1. A retrospective 15-year review: survival advantage after switching to sirolimus in hepatitis C virus infected liver graft recipients.
    Shah M; Shankar A; Gee I; Nash K; Hoare M; Gibbs P; Davies S; Alexander GJ
    Aliment Pharmacol Ther; 2015 Feb; 41(4):379-92. PubMed ID: 25496225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching to sirolimus monotherapy for de novo tumors after liver transplantation. A preliminary experience.
    Jiménez-Romero C; Manrique A; Marqués E; Calvo J; Sesma AG; Cambra F; Abradelo M; Sterup RM; Olivares S; Justo I; Colina F; Moreno E
    Hepatogastroenterology; 2011; 58(105):115-21. PubMed ID: 21510297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.
    Zhou J; Fan J; Wang Z; Wu ZQ; Qiu SJ; Huang XW; Yu Y; Sun J; Xiao YS; He YF; Wang YQ; Tang ZY
    World J Gastroenterol; 2006 May; 12(19):3114-8. PubMed ID: 16718799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus reduces the risk of significant hepatic fibrosis after liver transplantation for hepatitis C virus: a single-center experience.
    Kelly MA; Kaplan M; Nydam T; Wachs M; Bak T; Kam I; Zimmerman MA
    Transplant Proc; 2013 Nov; 45(9):3325-8. PubMed ID: 24182811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De novo cancer avoidance after renal transplantation: A case-control study on low-dose sirolimus combined with a calcineurin inhibitor.
    Chen KH; Lee CY; Wu FL; Yang CY; Yeh CC; Hu RH; Tsai MK
    J Formos Med Assoc; 2015 Jun; 114(6):526-31. PubMed ID: 25843527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database.
    Watt KD; Dierkhising R; Heimbach JK; Charlton MR
    Liver Transpl; 2012 Sep; 18(9):1029-36. PubMed ID: 22641474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
    Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to sirolimus-based immune suppression after liver transplantation is safe and effective: a single-center experience.
    Harper SJ; Gelson W; Harper IG; Alexander GJ; Gibbs P
    Transplantation; 2011 Jan; 91(1):128-32. PubMed ID: 21452417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus in liver transplant recipients: a large single-center experience.
    Vivarelli M; Dazzi A; Cucchetti A; Gasbarrini A; Zanello M; Di Gioia P; Bianchi G; Tamè MR; Gaudio MD; Ravaioli M; Cescon M; Grazi GL; Pinna AD
    Transplant Proc; 2010 Sep; 42(7):2579-84. PubMed ID: 20832548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
    Toso C; Meeberg GA; Bigam DL; Oberholzer J; Shapiro AM; Gutfreund K; Ma MM; Mason AL; Wong WW; Bain VG; Kneteman NM
    Transplantation; 2007 May; 83(9):1162-8. PubMed ID: 17496530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of immunosuppression minimization and withdrawal in long-term hepatitis C virus liver transplant recipients.
    Manzia TM; Angelico R; Ciano P; Mugweru J; Owusu K; Sforza D; Toti L; Tisone G
    World J Gastroenterol; 2014 Sep; 20(34):12217-25. PubMed ID: 25232255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation.
    Campbell MS; Rai J; Kozin E; Bloom RD; Markmann JF; Olthoff KM; Shaked A; Rajender Reddy K
    Clin Transplant; 2007; 21(3):377-84. PubMed ID: 17488388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of conversion to sirolimus monotherapy after liver transplant.
    Uhlmann D; Weber T; Ludwig S; Ludwig B; Bartels M; Hauss J; Jonas S; Witzigmann H
    Exp Clin Transplant; 2012 Feb; 10(1):30-8. PubMed ID: 22309417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus therapy in liver transplant patients: an initial experience at a single center.
    Nocera A; Andorno E; Tagliamacco A; Morelli N; Bottino G; Ravazzoni F; Casaccia M; Barocci S; Alice S; Santori G; Ghirelli R; Valente U
    Transplant Proc; 2008; 40(6):1950-2. PubMed ID: 18675098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus conversion in liver transplant recipients with calcineurin inhibitor-induced complications: efficacy and safety.
    Ju WQ; Guo ZY; Liang WH; Wu LW; Tai Q; Hu AB; Han M; Zhu XF; He X
    Exp Clin Transplant; 2012 Apr; 10(2):132-5. PubMed ID: 22432756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.
    Kneteman NM; Oberholzer J; Al Saghier M; Meeberg GA; Blitz M; Ma MM; Wong WW; Gutfreund K; Mason AL; Jewell LD; Shapiro AM; Bain VG; Bigam DL
    Liver Transpl; 2004 Oct; 10(10):1301-11. PubMed ID: 15376305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
    Geissler EK; Schnitzbauer AA; Zülke C; Lamby PE; Proneth A; Duvoux C; Burra P; Jauch KW; Rentsch M; Ganten TM; Schmidt J; Settmacher U; Heise M; Rossi G; Cillo U; Kneteman N; Adam R; van Hoek B; Bachellier P; Wolf P; Rostaing L; Bechstein WO; Rizell M; Powell J; Hidalgo E; Gugenheim J; Wolters H; Brockmann J; Roy A; Mutzbauer I; Schlitt A; Beckebaum S; Graeb C; Nadalin S; Valente U; Turrión VS; Jamieson N; Scholz T; Colledan M; Fändrich F; Becker T; Söderdahl G; Chazouillères O; Mäkisalo H; Pageaux GP; Steininger R; Soliman T; de Jong KP; Pirenne J; Margreiter R; Pratschke J; Pinna AD; Hauss J; Schreiber S; Strasser S; Klempnauer J; Troisi RI; Bhoori S; Lerut J; Bilbao I; Klein CG; Königsrainer A; Mirza DF; Otto G; Mazzaferro V; Neuhaus P; Schlitt HJ
    Transplantation; 2016 Jan; 100(1):116-25. PubMed ID: 26555945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
    Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
    Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.